Susquehanna International Group’s Enlivex Therapeutics ENLV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-10,833
| Closed | -$10.5K | – | 6585 |
|
|
2025
Q1 | $10.5K | Sell |
10,833
-326
| -3% | -$316 | ﹤0.01% | 6215 |
|
|
2024
Q4 | $13.1K | Buy |
+11,159
| New | +$13.1K | ﹤0.01% | 6029 |
|
|
2024
Q2 | – | Sell |
-67,943
| Closed | -$258K | – | 5867 |
|
|
2024
Q1 | $258K | Buy |
67,943
+40,018
| +143% | +$152K | ﹤0.01% | 4386 |
|
|
2023
Q4 | $75.4K | Buy |
+27,925
| New | +$75.4K | ﹤0.01% | 5441 |
|
|
2023
Q3 | – | Hold |
0
| – | – | – | 5765 |
|
|
2023
Q2 | – | Hold |
0
| – | – | – | 5872 |
|
|
2023
Q1 | – | Hold |
0
| – | – | – | 6161 |
|
|
2022
Q4 | – | Hold |
0
| – | – | – | 6080 |
|
|
2022
Q3 | – | Hold |
0
| – | – | – | 6318 |
|
|
2022
Q2 | – | Sell |
-36,560
| Closed | -$205K | – | 6035 |
|
|
2022
Q1 | $205K | Buy |
36,560
+25,276
| +224% | +$142K | ﹤0.01% | 4790 |
|
|
2021
Q4 | $71K | Buy |
+11,284
| New | +$71K | ﹤0.01% | 5392 |
|
|
2021
Q3 | – | Sell |
-21,493
| Closed | -$191K | – | 5506 |
|
|
2021
Q2 | $191K | Sell |
21,493
-26,613
| -55% | -$236K | ﹤0.01% | 4867 |
|
|
2021
Q1 | $533K | Buy |
48,106
+16,795
| +54% | +$186K | ﹤0.01% | 3770 |
|
|
2020
Q4 | $264K | Buy |
+31,311
| New | +$264K | ﹤0.01% | 4024 |
|
|
2018
Q2 | – | Sell |
-2,402
| Closed | -$38K | – | 3892 |
|
|
2018
Q1 | $38K | Buy |
2,402
+386
| +19% | +$6.11K | ﹤0.01% | 3163 |
|
|
2017
Q4 | $37K | Buy |
+2,016
| New | +$37K | ﹤0.01% | 3474 |
|